BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci 2015;60:3075-84. [PMID: 26044830 DOI: 10.1007/s10620-015-3735-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
2 Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
3 Alhalabi M, Eddin KA, Cheha K, Abbas A. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report. Medicine (Baltimore) 2021;100:e27283. [PMID: 34559136 DOI: 10.1097/MD.0000000000027283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Mahmoud R, van Lieshout C, Frederix GWJ, Jharap B, Oldenburg B. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. J Crohns Colitis 2021;15:709-18. [PMID: 33125060 DOI: 10.1093/ecco-jcc/jjaa219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Adedokun OJ, Xu Z, Marano C, O’brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:2244-2255.e9. [DOI: 10.1016/j.cgh.2019.11.059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
7 Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-60. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
8 Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24:2461-2467. [PMID: 29788240 DOI: 10.1093/ibd/izy171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
9 Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 2019;35:1911-23. [DOI: 10.1080/03007995.2019.1631058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
10 Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, Bertoletti F, Martínez-Montiel P, Sierra-Ausin M, Manceñido N, Lázaro Pérez-Calle J, Algaba A, Olivares D, Alba C. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin 2019;35:1297-304. [PMID: 30722703 DOI: 10.1080/03007995.2019.1579557] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Macaluso FS, Cavallaro F, Felice C, Mazza M, Armuzzi A, Gionchetti P, Vecchi M, Orlando A. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. Dig Liver Dis 2019;51:613-20. [PMID: 30826279 DOI: 10.1016/j.dld.2019.01.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Rizzello F, Salice M, Calabrese C, Mazza M, Calafiore A, Calandrini L, Hrustemovic HP, Campieri M, Gionchetti P. Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role? Ulcerative Colitis 2019. [DOI: 10.1007/978-88-470-3977-3_6] [Reference Citation Analysis]
13 Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model. Inflammatory Bowel Diseases 2018;24:286-95. [DOI: 10.1093/ibd/izx045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Capri S, Russo A. I costi dei pazienti con patologie infiammatorie dell’intestino (Malattia di Crohn e colite ulcerosa). Studio real world in Italia. Global & Regional Health Technology Assessment 2018;2018:228424031879328. [DOI: 10.1177/2284240318793281] [Reference Citation Analysis]
15 Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2018;9:221-231. [PMID: 30047549 DOI: 10.1136/flgastro-2017-100895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
16 Minar P, Dykes DM, Arce-clachar AC, Saeed SA. Infliximab Therapy for Pediatric Crohn Disease and Ulcerative Colitis. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_32] [Reference Citation Analysis]
17 Taxonera C, Iglesias E, Muñoz F, Calvo M, Barreiro-de Acosta M, Busquets D, Calvet X, Rodríguez A, Pajares R, Gisbert JP, López-Serrano P, Pérez-Calle JL, Ponferrada Á, De la Coba C, Bermejo F, Chaparro M, Olivares D, Alba C, Fernández-Blanco I. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. Dig Dis Sci 2017;62:481-90. [PMID: 27995400 DOI: 10.1007/s10620-016-4398-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
18 Thorne K, Alrubaiy L, Akbari A, Samuel DG, Morrison-Rees S, Roberts SE. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol 2016;28:369-82. [PMID: 26825217 DOI: 10.1097/MEG.0000000000000568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
19 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies: . Inflammatory Bowel Diseases 2016;22:1999-2015. [DOI: 10.1097/mib.0000000000000772] [Cited by in Crossref: 75] [Cited by in F6Publishing: 76] [Article Influence: 12.5] [Reference Citation Analysis]
20 Chaparro M, Gisbert J. Protocolo diagnóstico y terapéutico de un brote grave de colitis ulcerosa. Medicine - Programa de Formación Médica Continuada Acreditado 2016;12:256-259. [DOI: 10.1016/j.med.2016.02.022] [Reference Citation Analysis]